- Home
- PHAR vs HDL Comparison
PHAR vs HDL Comparison
Compare PHAR & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHAR | HDL |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | Netherlands | Singapore |
| Employees | N/A | 13651 |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 941.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PHAR | HDL |
|---|---|---|
| Price | $16.60 | $14.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $39.00 | N/A |
| AVG Volume (30 Days) | ★ 17.7K | 1.1K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.04 | $16.82 |
| Revenue Next Year | $2.51 | $14.44 |
| P/E Ratio | $3,041.22 | ★ $55.56 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.79 | $14.25 |
| 52 Week High | $21.34 | $23.62 |
Technical Indicators
Market Signals| Indicator | PHAR | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 55.12 | 32.17 |
| Support Level | $16.55 | N/A |
| Resistance Level | $17.60 | $17.71 |
| Average True Range (ATR) | 0.61 | 0.28 |
| MACD | 0.15 | -0.13 |
| Stochastic Oscillator | 81.86 | 0.00 |
Price Performance
Historical ComparisonAbout PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.